Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Propel Bio Management LLC

Propel Bio Management LLC increased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 60.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 133,259 shares of the company's stock after acquiring an additional 50,000 shares during the period. Syndax Pharmaceuticals makes up approximately 1.5% of Propel Bio Management LLC's portfolio, making the stock its 13th biggest holding. Propel Bio Management LLC owned 0.16% of Syndax Pharmaceuticals worth $2,565,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SNDX. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Syndax Pharmaceuticals in the third quarter valued at $15,165,000. First Turn Management LLC acquired a new stake in Syndax Pharmaceuticals in the second quarter valued at $13,147,000. Vanguard Group Inc. grew its holdings in Syndax Pharmaceuticals by 13.6% in the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company's stock valued at $117,262,000 after purchasing an additional 591,631 shares during the last quarter. Sofinnova Investments Inc. grew its holdings in Syndax Pharmaceuticals by 33.9% in the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company's stock valued at $44,215,000 after purchasing an additional 545,129 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Syndax Pharmaceuticals by 56.3% in the second quarter. Millennium Management LLC now owns 1,065,508 shares of the company's stock valued at $21,875,000 after acquiring an additional 383,634 shares in the last quarter.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock traded down $0.23 during trading hours on Tuesday, reaching $16.50. The company had a trading volume of 896,301 shares, compared to its average volume of 1,169,988. Syndax Pharmaceuticals, Inc. has a twelve month low of $15.00 and a twelve month high of $25.34. The company has a market capitalization of $1.41 billion, a P/E ratio of -4.52 and a beta of 0.92. The stock's fifty day simple moving average is $18.57 and its 200 day simple moving average is $19.93.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter last year, the business posted ($0.73) EPS. As a group, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -3.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on SNDX shares. UBS Group started coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a "buy" rating and a $37.00 price objective on the stock. Bank of America upped their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, August 15th. Barclays upped their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research report on Thursday, August 15th. Citigroup upped their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, November 19th. Finally, StockNews.com downgraded Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $37.64.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).